References
- Price KE. Aminoglycoside research 1975–1985: prospects for development of improved agents. Antimicrob Agents Chemother 1986; 29: 543–548
- Lietman PS. Aminoglycosides and spectinomycin: aminocyclitols. Principles and practice of infectious diseases, G.L. Mandell, R.G. Douglas, J.E. Bennet. John Wiley & Sons, New York 1985; pp 192–206
- Frame P T, Phair J P, Watanakunakom C., Bannister TWP. Pharmacologic factors associated with gentamicin nephrotoxicity in rabbits. J Infect Dis 1977; 135: 952–956
- Bennett W M, Plamp C E, Gilbert D N, Parker R A, Porter G A. The influence of dosage regimen on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure. J Infect Dis 1979; 140: 576–580
- Wood C A, Norton D R, Kohlhepp S J, Kohnen P W, Porter G A, Houghton D C, Brummett R E, Bennett W M, Gilbert D N. The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess. J Infect Dis 1988; 158: 13–22
- Pechere J C, Bernard P A. Gentamicin ototoxicity can be avoided if a new therapeutic regimen is used. An experimental model. In 24th Intersc Conf Antimicrob Agents Chemother, Washington (DC), Vol A 484. 1984
- Tran Ba Huy P. Aminoglycoside ototoxicity: influence of dosage regimen on drug uptake, correlation between membrane binding and clinical features. J Drug Dev 1988; 1(suppl. 3)93–95
- Craig W A, Leggett J, Totsuka K, Vogelman B. Key pharmacokinetic parameters of antibiotic efficacy in experimental animal infections. JDrug Dev 1988; 1(Suppl.3): 7–15
- Tulkens PM. Experimental studies on nephrotoxicity of aminoglyco-sides at low doses: mechanisms and perspectives. Am J Med 1986; 80(6B)105–114
- Tulkens PM. Nephrotoxicity of aminoglycosides. Toxicol Lett 1989; 46: 107–123
- Ibrahim S, van der Auwera P, Meunier F, Tulkens P M. Effect of amikacin and netilmicin on urinary phospholipids excretion in humans. Arch Toxicol Suppl 1989; 13: 413–416
- Sawchuk R J, Zaske D E. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. JPharma cokinetBiopharm 1976; 4: 183–195
- Sawchuk R J, Zaske DE, Cipolle R J, Wargin W A, Strate R G. Kinetic model for gentamicin dosing with the use of individual patient parameters. Clin Pharm Ther 1977; 21: 362–366
- Schentag JJ. Aminoglycoside pharmacokinetics as a guide to therapy and toxicology. The Aminoglycosides: microbiology, clinical use and toxicology, A. Whelton, H.C. Neu. Marcel Dekker lnc., New York 1982; pp 143–157
- Hollender L F, Bahnini J, De Manzini N, Lau WY, Fan S T, Herman-syur K, Benny P, Husni A N, Sutjipto, Lorber RR. A multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra-abdominal infections. J Antimicrob Chemoth 1989; 23: 773–784
- Sturm AW. Netilmicin in the treatment of Gram-negative bactere-mia: single daily versus multiple daily dosage. J Infect Dis 1989; 159: 931–937
- De Broe M E, Paulus G J, Verpooten G A, Giuliano R A, Roels F, Tulkens P M. Early toxicity of aminoglycosides in human kidney: a prospective, comparative study of amikacin, gentamicin, netilmicin and tobramycin. In Proceedings of the 13th International Congress of Chemotherapy, Vienna, Vol. 86 (Spitzy K. H., Karrer K. eds). 11–24, 1983
- Brummett R E, Fox K E. Aminoglycoside-induced hearing loss in humans. Antimicrob Agents Chemother 1989; 33: 797–800